How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma
Authors:
- Giulia MartiniGiulia Martini
- Davide CiardielloDCDavide Ciardiello
- Fernando ParagliolaFPFernando Paragliola
- Valeria NaccaVNValeria Nacca
- Walter SantanielloWSWalter Santaniello
- Fabrizio UrraroFUFabrizio Urraro
- Maria StanzioneMSMaria Stanzione
- Marco NiosiMNMarco Niosi
- Marcello DallioMDMarcello Dallio
- Alessandro FedericoAlessandro Federico
- Francesco SelvaggiFSFrancesco Selvaggi
- Carminia Maria Della CorteCarminia Maria Della Corte
Open Access
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of death worldwide. The use of local treatment, such as surgical resection, liver transplant, and local ablation, has improved the survival of patients with HCC detected at an early stage. Until recently, the treatment of patients with metastatic disease was limited to the use of the multikinase inhibitor (MKI) sorafenib with a marginal effect on survival outcome. New target approaches, such as the oral MKI lenvatinib in first-line treatment and regorafenib, ramucirumab, and cabozantinib in later lines of therapy, have demonstrated efficacy in patients with preserved liver function (Child–Pugh class A) and good performance status. On the other hand, the implementation of immune checkpoint inhibitors directed against PD-1 (nivolumab and pembrolizumab), PD-L1 (atezolizumab), and anti-CTLA4 (ipilimumab) in the management of advanced HCC has strongly changed the continuum of care of HCC. Future research should include the evaluation of molecular biomarkers that can help patient selection and provide new insight on potential combined approaches. In this review, we provide an overview of the clinical evidence of the use of immune checkpoint inhibitors in HCC, and discuss how immunotherapy has been implemented into the continuum of HCC care.Keywords
This publication has 55 references indexed in Scilit:
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis CJournal of Hepatology, 2013
- Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall SurvivalClinical Cancer Research, 2012
- Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination EfficacyMolecular Therapy, 2011
- Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular CarcinomaMolecular Therapy, 2010
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma†Hepatology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialThe Lancet Oncology, 2008
- Analysis of CD4+ T-Cell Responses to a Novel α-Fetoprotein-Derived Epitope in Hepatocellular Carcinoma PatientsClinical Cancer Research, 2005
- Hepatic T cells and liver toleranceNature Reviews Immunology, 2003
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999